Document Classification

Section Type: RESULTS

Text: Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis : a smaller mean (+ / - SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0. 09 + / -0. 02 points per week in the early-start group vs. 0. 14 + / -0. 01 points per week in the placebo group, P = 0. 01), less worsening in the score between baseline and week 72 (2. 82 + / -0. 53 points in the early-start group vs. 4. 52 + / -0. 56 points in the delayed-start group, P = 0. 02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0. 085 + / -0. 02 points per week in the early-start group vs. 0. 085 + / -0. 02 points per week in the delayed-start group, P < 0. 001).